Adamax

No. Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro. Adamax takes that scaffold and modifies both ends, adding an N-terminal acetyl group and a C-terminal Ala-Gly extension to give a nonapeptide. Chemically modest as those changes sound, they make Adamax a distinct molecule whose properties cannot simply be assumed from the parent. Semax has a genuine preclinical literature, including receptor binding and BDNF work in rat brain; Adamax has none of its own, so findings from one must not be silently attributed to the other.

Essentially none. No peer-reviewed binding studies, in-vitro characterisation, animal pharmacology or toxicology on Adamax appear in the indexed literature. We state this plainly because it is the single most important fact about the compound. The only relevant published science is on the parent compound Semax, and it is labelled as such wherever it is cited on this page. Anywhere you see confident mechanistic claims about Adamax specifically, they are extrapolation, not evidence.

The two papers cited on this page, both from Dolotov and colleagues in 2006 and both clearly labelled parent compound Semax literature, report that Semax binds specifically and increases brain-derived neurotrophic factor protein levels in rat basal forebrain (PubMed 16635254), and that it regulates BDNF and trkB expression in the rat hippocampus (PubMed 16996037). These are rodent findings about Semax. Whether the acetylated, extended Adamax analogue shares this behaviour is an open experimental question, which is precisely what an analogue-versus-parent study design would exist to test.

Because it has never been registered, which is itself a signal of how little formal characterisation the compound has received. A CAS registry number normally accompanies a substance into the indexed chemical and pharmacological literature; Adamax has neither. Identity therefore rests on the supplied documentation: the sequence, the stated mass, and the batch-specific certificate of analysis published on the product page, which for batch UKPL-472 states 99.2% purity by RP-HPLC on a supplier-reported basis, with independent verification pending.

Adamax may be purchased in the UK as a research chemical for in vitro laboratory use only. It is not an approved or licensed medicine in the UK and is not supplied for human consumption, veterinary use, or any therapeutic purpose. Purchasers must be 18 or over and confirm research-only use at checkout.

UK Peptide Lab sells Adamax 5mg from UK stock, batch UKPL-472. Orders placed before 3pm UK time on a working day are dispatched the same day. UK Royal Mail Tracked delivery is free over £59.

Not yet. Batch UKPL-472 carries a supplier-reported certificate stating 99.2% purity by RP-HPLC, published in full on the product page, and independent verification is pending. With no CAS number and no literature of its own, that batch certificate is the main identity document for the material.

Adamax has no published studies of its own, so there are no established research applications. It suits analogue-versus-parent designs against Semax, such as comparative stability assays or BDNF and trkB endpoint assays in neuronal culture.